P. LoRusso

415 citations

38 papers · 328 indexed · h-index 12

Impact in

Oncology
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Genetics

Papers in ⓘ

Cancer Research 13
- Cancer Genomics and Diagnostics 8
Oncology 18
- Cancer Treatment and Pharmacology 6
- Colorectal Cancer Treatments and Studies 5
- HER2/EGFR in Cancer Research 4

Co-authors: Geoffrey I. Shapiro (9 shared papers)Elisabeth I. Heath (5 shared papers)J. R. Infante (3 shared papers)Chad Zack (2 shared papers)Amy J. Wagner (2 shared papers)Daniel D. Von Hoff (2 shared papers)Shirish M. Gadgeel (2 shared papers)Raghu Venkatramanamoorthy (1 shared paper)
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (3 papers)European Journal of Cancer (3 papers)European Journal of Cancer Supplements (11 papers)Cancer Research (1 paper)
Partner nations: United States Japan France

In The Last Decade

P. LoRusso

37 papers receiving 319 citations

Peers

Countries citing papers authored by P. LoRusso

Since Specialization

Citations

This map shows the geographic impact of P. LoRusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. LoRusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. LoRusso more than expected).

Fields of papers citing papers by P. LoRusso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. LoRusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. LoRusso. The network helps show where P. LoRusso may publish in the future.

Co-authors

The 25 scholars most cited alongside P. LoRusso, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. LoRusso Line = papers co-authored together P. LoRusso links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. Journal of Clinical Oncology ·Andrés Cervantes, María Alsina, Josep Tabernero, J. R. Infante, P. LoRusso, Geoffrey I. Shapiro, Luis Paz‐Ares, Rick Falzone, Jamie Hill, Jeff Cehelsky, Anne White, Iva Toudjarska, David Bumcrot, R. Meyers, Gregory Hinkle, Nenad Svrzikapa, Dinah W.Y. Sah, Akshay Vaishnaw, Jared Gollob, H. A. Burris	2011	44
2	Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC) Journal of Clinical Oncology ·Shirish M. Gadgeel, A. Wozniak, Martin J. Edelman, Manuel Valdivieso, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Andrew Shields, P. LoRusso, Deborah Hackstock, John Ruckdeschel	2009	28
3	A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology ·Daniel D. Von Hoff, P. LoRusso, G. D. Demetri, Glen J. Weiss, Geoffrey I. Shapiro, Rajesh Ramanathan, J. A. Ware, Rajiv Raja, Jiangtao Jin, G. G. Levy, Kathryn Mazina, Amy J. Wagner	2011	25
4	A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Cristian Moldovan, Jean‐Charles Soria, P. LoRusso, Tina Guthrie, Changhoon Song, Linh T. Nguyen, J.-F. Martini, J. R. Infante, Howard A. Burris	2010	18
5	A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. Journal of Clinical Oncology ·D. C. Cho, Elisabeth I. Heath, J. M. Cleary, E. L. Kwak, Leena Gandhi, Donald P. Lawrence, Chad Zack, Florentina Teofilovici, Robert H. Bradley, Michael D. Karol, Geoffrey I. Shapiro, P. LoRusso	2011	15
6	A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors Journal of Clinical Oncology ·E. A. Sausville, P. LoRusso, Mary Quinn, Karen Forman, Christopher P. Leamon, Daniel Morganstern, S. Bever, Richard A. Messmann	2007	14
7	A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors. Journal of Clinical Oncology ·J. M. Cleary, Elisabeth I. Heath, E. L. Kwak, Bruce J. Dezube, Leena Gandhi, Chad Zack, R. H. E. Bradley, Vojo Vukovic, Geoffrey I. Shapiro, P. LoRusso	2010	14
8	Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers Journal of Clinical Oncology ·Serajuddaula Syed, M. Beeram, Chris H. Takimoto, J. Jakubowitz, Masayuki Kimura, M. Ducharme, S. Gadgeel, Robert De Jager, Eric K. Rowinsky, P. LoRusso	2004	13
9	A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors European Journal of Cancer ·Andreea Varga, J.C. Soria, Antoine Hollebecque, P. LoRusso, Ulka N. Vaishampayan, Kwame Okrah, Sida Huang, Elaine Murray, Sandra Sanabria Bohórquez, Mike Tagen, Hatem Dokainish, Lars Müeller, H. Burris	2016	13
10	Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Edward A. Sausville, P. LoRusso, Michael A. Carducci, Peter Barker, Felix Agbo, Patricia Oakes, Adrian M. Senderowicz	2011	12
11	Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. Journal of Clinical Oncology ·P. LoRusso, Ian E. Krop, H.A. Burris, Svetislava J. Vukelja, KD Miller, Maoxia Zheng, Y.-W. Chu, Mengdi Lu, Lukas C. Amler, H. S. Rugo	2010	12
12	A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors. Journal of Clinical Oncology ·Colin D. Weekes, P. LoRusso, V. Ramakrishnan, L-Y Shih, Walter C. Darbonne, Priti S. Hegde, Xin Yan, R. Yu, Hong Xiang, R. Brachmann, Amita Patnaik	2011	11
13	Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study Cancer Research ·Hans Wildiers, S-B. Kim, Antonio González-Martı́n, P. LoRusso, J-M Ferrero, Ron Yu, Melanie C. Smitt, IE Krop	2016	11
14	Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas European Journal of Cancer ·Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz, P. LoRusso, Parveen Kumar, Kazuki Kato, Bei Tao, Young‐Rock Hong, Pratik Patel, Hong Dai	2020	10
15	Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients. Journal of Clinical Oncology ·Walter C. Darbonne, Xing Du, Punita Dhawan, Dylan P. Hartley, Jacqueline M. Tarrant, Helen R. Taylor, Gary Cain, L-Y Shih, R. Brachmann, Quentin Phung, Colin D. Weekes, P. LoRusso, A. Patnaik, Hong Xiang, V. Ramakrishnan	2011	10
16	216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors European Journal of Cancer Supplements ·B. Markman, P. LoRusso, Akash Patnaik, Elisabeth I. Heath, Alexander Laird, Barbara L. van Leeuwen, K. Papadopoulos, José Baselga	2008	10
17	381 Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) in patients with advanced malignancies European Journal of Cancer Supplements ·A. W. Tolcher, K. Papadopolous, A. Patniak, Elisabeth I. Heath, Amy Weise, T. Prokop, Stefania Morrone, James A. Zanghi, Harold Keer, P. LoRusso	2010	8
18	A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·J. Berlin, Vicki L. Keedy, Pasi A. Jänne, Lorrin Yee, Naiyer A. Rizvi, Xin Jin, Catherine Copigneaux, Thore Hettmann, Darrin M. Beaupre, P. LoRusso	2011	7
19	588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies European Journal of Cancer ·Wells A. Messersmith, P. LoRusso, James M. Cleary, Arvind Dasari, Bin Huang, Naveed Shaik, Rossano Cesari, Karen R. McLachlan, Katharina Kern, Geoffrey I. Shapiro	2012	7
20	Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. Journal of Clinical Oncology ·Jared Gollob, J. R. Infante, Geoffrey I. Shapiro, P. LoRusso, Bruce J. Dezube, John V. Heymach, Jeff Cehelsky, Rick Falzone, Akshay Vaishnaw, Howard A. Burris	2010	7

About P. LoRusso

P. LoRusso is a scholar working on Cancer Research, Oncology, Biotechnology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 38 papers that have together received 328 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (8 papers), Cancer Treatment and Pharmacology (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer Research and Treatments (4 papers), HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (4 papers) and Protein Degradation and Inhibitors (3 papers). The work is most often cited by research in Oncology (143 citations), Genetics (38 citations), Molecular Biology (229 citations), Cancer Research (43 citations) and Pulmonary and Respiratory Medicine (84 citations). P. LoRusso has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Geoffrey I. Shapiro, Elisabeth I. Heath, J. R. Infante, Chad Zack, Amy J. Wagner, Daniel D. Von Hoff, Shirish M. Gadgeel, Raghu Venkatramanamoorthy, J. A. Ware and Howard A. Burris. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, European Journal of Cancer Supplements and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact